Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) tumbled 5.01% during intraday trading on Wednesday, as analysts significantly lowered their revenue estimates and price targets for the pharmaceutical company.
According to the latest analyst coverage, the consensus revenue estimate for Ironwood Pharmaceuticals in 2024 has been slashed by 13% to $356 million, reflecting a notable 11% decline from its sales over the past 12 months. The analysts cited a weaker outlook for the company, signaling that investors should temper their expectations.
Furthermore, the consensus price target for Ironwood Pharmaceuticals has been cut by 21% to $12.50, indicating that analysts are less optimistic about the company's valuation following the downward revisions to revenue estimates. The analysts' forecasts imply that Ironwood Pharmaceuticals' revenue growth is expected to significantly underperform the wider industry, with an annualized revenue decline of 21% by the end of 2024, compared to an industry average growth of 23%.
Comments